317 related articles for article (PubMed ID: 11597453)
1. The pathogenesis of Ebola hemorrhagic fever.
Takada A; Kawaoka Y
Trends Microbiol; 2001 Oct; 9(10):506-11. PubMed ID: 11597453
[TBL] [Abstract][Full Text] [Related]
2. [Properties of the Ebola virus glycoprotein].
Takada A
Uirusu; 2006 Jun; 56(1):117-24. PubMed ID: 17038820
[TBL] [Abstract][Full Text] [Related]
3. Ebola virus pathogenesis: implications for vaccines and therapies.
Sullivan N; Yang ZY; Nabel GJ
J Virol; 2003 Sep; 77(18):9733-7. PubMed ID: 12941881
[No Abstract] [Full Text] [Related]
4. Ebolavirus VP35 is a multifunctional virulence factor.
Leung DW; Prins KC; Basler CF; Amarasinghe GK
Virulence; 2010; 1(6):526-31. PubMed ID: 21178490
[TBL] [Abstract][Full Text] [Related]
5. [Research progress on ebola virus glycoprotein].
Ding GY; Wang ZY; Gao L; Jiang BF
Bing Du Xue Bao; 2013 Mar; 29(2):233-7. PubMed ID: 23757858
[TBL] [Abstract][Full Text] [Related]
6. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
7. [Research progress of the molecule mechanisms of Ebola virus infection of cells].
Shi M; Shen YQ
Bing Du Xue Bao; 2013 Jan; 29(1):71-5. PubMed ID: 23547383
[TBL] [Abstract][Full Text] [Related]
8. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.
Yang ZY; Duckers HJ; Sullivan NJ; Sanchez A; Nabel EG; Nabel GJ
Nat Med; 2000 Aug; 6(8):886-9. PubMed ID: 10932225
[TBL] [Abstract][Full Text] [Related]
9. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
Parren PW; Geisbert TW; Maruyama T; Jahrling PB; Burton DR
J Virol; 2002 Jun; 76(12):6408-12. PubMed ID: 12021376
[TBL] [Abstract][Full Text] [Related]
10. Antibody-dependent enhancement of Ebola virus infection.
Takada A; Feldmann H; Ksiazek TG; Kawaoka Y
J Virol; 2003 Jul; 77(13):7539-44. PubMed ID: 12805454
[TBL] [Abstract][Full Text] [Related]
11. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions.
Geisbert TW; Hensley LE
Expert Rev Mol Med; 2004 Sep; 6(20):1-24. PubMed ID: 15383160
[TBL] [Abstract][Full Text] [Related]
12. Infectivity-enhancing antibodies to Ebola virus glycoprotein.
Takada A; Watanabe S; Okazaki K; Kida H; Kawaoka Y
J Virol; 2001 Mar; 75(5):2324-30. PubMed ID: 11160735
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSVΔG/EBOVgp).
Barrenas F; Green RR; Thomas MJ; Law GL; Proll SC; Engelmann F; Messaoudi I; Marzi A; Feldmann H; Katze MG
Clin Vaccine Immunol; 2015 Mar; 22(3):354-6. PubMed ID: 25589554
[TBL] [Abstract][Full Text] [Related]
14. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
15. Ebola virus: the search for vaccines and treatments.
Wilson JA; Bosio CM; Hart MK
Cell Mol Life Sci; 2001 Nov; 58(12-13):1826-41. PubMed ID: 11766882
[TBL] [Abstract][Full Text] [Related]
16. Positive evolution of the glycoprotein (GP) gene is related to transmission of the Ebola virus.
Jing YX; Wang LN; Wu XM; Song CX
Genet Mol Res; 2016 Mar; 15(1):. PubMed ID: 27051001
[TBL] [Abstract][Full Text] [Related]
17. Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin.
Usami K; Matsuno K; Igarashi M; Denda-Nagai K; Takada A; Irimura T
Biochem Biophys Res Commun; 2011 Apr; 407(1):74-8. PubMed ID: 21362405
[TBL] [Abstract][Full Text] [Related]
18. Successful topical respiratory tract immunization of primates against Ebola virus.
Bukreyev A; Rollin PE; Tate MK; Yang L; Zaki SR; Shieh WJ; Murphy BR; Collins PL; Sanchez A
J Virol; 2007 Jun; 81(12):6379-88. PubMed ID: 17428868
[TBL] [Abstract][Full Text] [Related]
19. Progress towards the treatment of Ebola haemorrhagic fever.
Ströher U; Feldmann H
Expert Opin Investig Drugs; 2006 Dec; 15(12):1523-35. PubMed ID: 17107278
[TBL] [Abstract][Full Text] [Related]
20. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.
Pushko P; Bray M; Ludwig GV; Parker M; Schmaljohn A; Sanchez A; Jahrling PB; Smith JF
Vaccine; 2000 Aug; 19(1):142-53. PubMed ID: 10924796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
